Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members
Summary:
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.
Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides
Summary:
The NCI is looking for innovative companies interested in co-developing and/or licensing a novel nucleic-based therapy based on the conditional activation strategy.
Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers
Description of Technology:
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.
Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images
Summary:
The National Cancer Institute (NCI) Laboratories of Pathology and Cancer Biology and Genetics are seeking parties interested in licensing and/or partnering in co-development research of a software tool for commercialization in the field of clinical immunohistochemistry quantification.
Mitotic Figures Electronic Counting Application for Surgical Pathology
Summary:
The National Cancer Institute (NCI) Laboratory of Cancer Biology and Genetics is seeking parties interested in licensing and /or co-development research collaboration of a software application for commercialization in quantitative and digital pathology fields.
Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276
Summary:
The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.
Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy
Description of Technology:
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells.
Mouse Embryo Culture Chamber and Imaging System and Methods of Use
Description of Technology:
The culture of mouse embryos ex utero and continuous monitoring and imaging of embryos as they develop have applications in drug testing, genetic studies, and basic research on embryonic development. However, the embryo culture systems currently available for post-implantation embryos include rolling bottle culture systems, which do not permit imaging of the developing embryos and do not support the long-term survival and development of embryos ex utero.
Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment
Description of Technology:
Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth.
Antisense Oligonucleotides against Cancer Cell Migration and Invasion
Summary:
NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.